肝乐宁联合拉米夫定治疗慢性乙型肝炎的临床研究  

Clinical efficiency of Ganlening combined with Lamivudine in treating chronic hepatitis B

作　　者：梁雪峰 潘美瑞[2] 于德奎 李玉华 荆慧 姜明东 

机构地区：[1]河北省德州市卫生防疫站,253014 [2]德州市人民医院

出　　处：《职业与健康》2004年第11期169-170,共2页Occupation and Health

摘　　要：目的探讨肝乐宁联合拉米夫定治疗慢性乙肝的临床疗效。方法治疗组31例慢性乙肝病人每日静脉输入肝乐宁100mg,对照组34例每日静脉输入甘草酸二铵150mg,输液治疗30d,两组均口服降酶保肝药和拉米夫定100mg/d,疗程30d。结果30d后,治疗组ALT复常率达90.3%,对照组只有52.9%,两者差异有显著性(P<0.01),治疗组白蛋白含量上升,1～2g/L,HBeAg阴转率(7.8%)略高于对照组。结论肝乐宁联合拉米夫定即能明显改善肝脏功能,减少纤维化,又能有效地抑制HBVONA的复制,能使受损的肝脏得到尽快的恢复,我们认为此方案效果比较理想。Objective] To study the clinical efficiency of Ganlening combined with Lamivudine in treating chronic hepatitis B. [Methods] 31 cases of the case group received vein input of Ganlening, 100 mg per day; 34 cases of the control group received vein input of Diammonium glycyrrhizic acid, 150 mg per day, both the two groups received vein input for 30 days and oral intake of ALT-reducing and liver-protecting drugs and Lamivudine with a dose of 100 mg per day for 30 days. [Results] After 30 days, the ALT resuming rate of the case group was 90.3%, that of the control group was 52.9%, the difference was significant (P<0.01). Albumin of the case group increased by 1～2 g/L; negative returning rate was 7.8%, which was slightly higher than that of the control group. [Conclusion] Ganlening combined with Lamivudine can significantly improve the liver function, reduce fibrosis and effectively restrain the copy of HBVONA. This method has an ideal effect in recovering the liver function.

关 键 词：慢性乙型肝炎 肝乐宁 拉米夫定 甘草酸二铵 

分 类 号：R453[医药卫生—治疗学]